News Novo Nordisk to cut GLP-1 prices in tough US market Novo Nordisk has turned to pricing as a means to shore up its position in the increasingly competitive market for GLP-1 agonist therapies in the US.
Market Access Policy in Focus: Unpacking GLOBE, GUARD, and TrumpRx with Al... Unpack the impact of Most-Favoured Nations in GLOBE and GUARD pricing models, and TrumpRx, with Alice Valder Curran's clear policy overview.
Patients On addressing drug waste and ensuring access, with Jeff Harp... The rising cost of drugs in 2025 was driven by several factors, including inflation, supply chain issues, and the demand for specialty drugs.
News White House's TrumpRx platform has arrived The Trump administration's long-promised direct-to-consumer (DTC) sales channel for medicines, TrumpRx, has finally gone live.
News Fears US drug pricing deal will weigh heavy on the NHS The UK confirms that the cost of the drug pricing deal with the US, initially around £1bn over three years, will be borne by the health department.
News CMS's Medicare price negotiations start round three The US federal government has named the next 15 big-selling medicines that will be subject to Medicare pricing negotiations.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.